4.4 Article

Learning from low-rank multimodal representations for predicting disease-drug associations

Journal

BMC MEDICAL INFORMATICS AND DECISION MAKING
Volume 21, Issue SUPPL 1, Pages -

Publisher

BMC
DOI: 10.1186/s12911-021-01648-x

Keywords

Disease-drug associations prediction; Low-rank tensors; Multimodal fusion

Funding

  1. Pioneer Hundred Talents Program of Chinese Academy of Sciences

Ask authors/readers for more resources

The LMFDA method introduces multimodal fusion using low-rank tensors to combine multiple similar networks and utilizes matrix complement technology for predicting potential associations. It demonstrates excellent network integration ability for accurate disease-drug association inference and shows significant improvement over advanced approaches. Experimental results indicate that LMFDA delivers excellent detection performance, suggesting that enhancing similar networks with domain knowledge is a promising direction for drug repositioning.
Background Disease-drug associations provide essential information for drug discovery and disease treatment. Many disease-drug associations remain unobserved or unknown, and trials to confirm these associations are time-consuming and expensive. To better understand and explore these valuable associations, it would be useful to develop computational methods for predicting unobserved disease-drug associations. With the advent of various datasets describing diseases and drugs, it has become more feasible to build a model describing the potential correlation between disease and drugs. Results In this work, we propose a new prediction method, called LMFDA, which works in several stages. First, it studies the drug chemical structure, disease MeSH descriptors, disease-related phenotypic terms, and drug-drug interactions. On this basis, similarity networks of different sources are constructed to enrich the representation of drugs and diseases. Based on the fused disease similarity network and drug similarity network, LMFDA calculated the association score of each pair of diseases and drugs in the database. This method achieves good performance on Fdataset and Cdataset, AUROCs were 91.6% and 92.1% respectively, higher than many of the existing computational models. Conclusions The novelty of LMFDA lies in the introduction of multimodal fusion using low-rank tensors to fuse multiple similar networks and combine matrix complement technology to predict potential association. We have demonstrated that LMFDA can display excellent network integration ability for accurate disease-drug association inferring and achieve substantial improvement over the advanced approach. Overall, experimental results on two real-world networks dataset demonstrate that LMFDA able to delivers an excellent detecting performance. Results also suggest that perfecting similar networks with as much domain knowledge as possible is a promising direction for drug repositioning.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available